What is Monopar Therapeutics's change in AP?

Monopar Therapeutics (MNPR) reported change in AP of -$287.14K in Q1 2026.

How has Monopar Therapeutics's change in AP changed year-over-year?

Monopar Therapeutics's change in AP increased by 62.8% year-over-year, from -$770.97K to -$287.14K.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

Monopar Therapeutics MNPR Change in AP

Change in AP at other companies

Bristol-Myers SquibbBMY

$409M+581%

Eli LillyLLY

$2.55B+290%

Bausch Health CompaniesBHC

-$150M-51.5%

Prime MedicinePRME

$3.55M+88.5%

Wave Life SciencesWVE

$3.29M+260%

Perspective TherapeuticsCATX

-$4.21M-146%

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's change in AP?: Monopar Therapeutics (MNPR) reported change in AP of -$287.14K in Q1 2026.
How has Monopar Therapeutics's change in AP changed year-over-year?: Monopar Therapeutics's change in AP increased by 62.8% year-over-year, from -$770.97K to -$287.14K.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.